Evaluate the Efficacy and Safety of TTYP01 Tablets in Adolescents and Children With ASD

Exclusion Criteria17

• Any participant who meets any of the following criteria will be excluded:
• Weight <20.0 kg or >70.0 kg, or BMI ≥35.0 kg/m\^2;
• Pregnant or lactating women;
• Presence of a serious mental disorder as assessed by the investigator, e.g., schizophrenia, bipolar disorder, depressive disorder, etc.; the presence of significant anxiety, tension, agitation, fear, depression, or the presence of suicidal risk, significant risk of self-injury, impulsivity, aggression, or behaviors based on the medical history and the routine mental status examination;
• History of epileptic seizures within 3 months prior to screening, or presence of a history of severe physical or neurological disease, history of severe head trauma;
• Participants with a history or symptoms of other mental illness that, at the discretion of the investigator, may affect the results of the study;
• Participants with a history of any unstable physical or neurological condition or currently suffering from a physical or neurological condition that, at the discretion of the investigator, may put them at risk of a significant adverse event or interfere with the assessment of safety and efficacy during the course of the trial;
• Pre-existing educational training and/or behavioral treatments fail to be stabilized prior to screening and consistent throughout the trial;
• Participants who are unable to discontinue or may use other treatments during the screening period and throughout the trial due to their condition, including: antipsychotic medications (except those that may be used in combination during the trial as specified in the protocol), medications that may have a therapeutic effect on ASD, nootropic drugs, medications for ADHD, intestinal flora modification, and other intestinal flora modification supplementation alternatives;
• Participants who have used treatment modalities such as transcranial magnetic stimulation therapy, direct current stimulation therapy, electroencephalographic biofeedback therapy, auditory integration training, executive function training, acupuncture therapy, etc., within 2 months prior to randomization, or may use such treatments during the treatment period;
• 12-ECG and laboratory results as outlined below: (1)QTc is outside the normal range of the site; (2)Platelets are below the lower limit of normal for the site; (3)Haemoglobin is below the lower limit of normal for the site; (4)Neutrophil count is below the lower limit of normal for the site; (5)ALT or AST ≥ 2 × upper limit of normal, or total bilirubin > upper limit of normal for the site; (6)Urea nitrogen or creatinine is above the upper limit of normal for the site; (7)Any other abnormal laboratory, vital sign, or 12-ECG findings that, at the discretion of the investigator, are abnormal and clinically significant and will affect the safety of the participant or the interpretation of the study results;
• Participation in any clinical trial of a drug or non-drug intervention within the last 1 month;
• Concomitant medications/therapies that are prohibited in the protocol may be required during the trial;
• Participants expected to undergo elective surgery during the trial;
• Participants whose parents/guardians are unable to understand and/or complete the scale assessments in this trial.
• Hypersensitivity to edaravone and excipients (Soluplus, sodium bisulphite, microcrystalline cellulose, magnesium stearate, polyvinylpolypyrrolidone) in TTYP01 tablets;
• Participants who are judged by the investigator to be ineligible for other reasons.